Huihe Medical Launches World's First S-Shaped Spiral Electrode IVL Catheter for Coronary Artery Calcification

#  C-Wave^®Coronary Shockwave Catheter

C-Wave^®Developed and manufactured by the Zhonghui team of HuiHe Healthcare,Retained the inherent characteristics of IVL：Activate the hydroelectric effect with shock wave energy, crush calcification to reach the middle membrane layer, and obtain the lumen;

MoreIterate on the balanced angular discharge for the short axis and the continuous discharge for the long axis., launched the C-Wave with independent intellectual property rights^®Coronary Shockwave Catheter.

Product Features:

S-shaped spiral electrode distribution:Considering the severity of calcification cross-sections and the continuity along the vessels in Chinese patients,Place 6 electrodes continuously along the long axis.Distributed in an "S" shape，ForContinuous calcification, nodular calcification, and eccentric calcified lesionsWith stronger opening capabilities.

Source: OfficialWeChat Official Account (the same below)）

Dual Electrode：Dual-electrode with clockwise and counterclockwise rotation,Double ElectrodeSimultaneous Stimulation. Each trigger can effectively activate 4 discharge points, generating 4 shock waves. Each catheter can be triggered 80 times.A maximum of 320 shockwave discharge points can be released.。

Source: Official WeChat Public Account (same below)

Complete range of models:Provide specifications for every 0.25mm increment, whose catheter (balloon) is available in 7 specifications ranging from 2.5mm to 4.00mm.

C-Wave^®The shock wave generator (host machine) is equipped with a 7-inch large display, which can show information such as catheter model, activation status, and number of activations.Meet Clinical Visualization Needs。

Global Patents:HuiHe Healthcare's C-Wave^®Globally, In ChinaApplied for 54 patents, 36 items have been authorized, of which 25 are invention patents.

# Company Profile

Shanghai Huihe Healthcare Technology Co., Ltd. was established in May 2019 and is a company focused onResearch and Production of Cardiovascular Implantable Devices, a technology enterprise with independent innovation capabilities.The company ownsThe four major platforms: R&D and production of delivery systems, clinical medical technology, precision manufacturing, and global marketing.Has industry-leading advantages. InCardiac valve intervention, vascular intervention, electrophysiological intervention, drug delivery intervention, and intelligent interventionIn fields such as these, they have independently developed, world-leading related products.

Under its umbrellaProducts Cover the HeartIn multiple fields such as valve intervention and vascular interventional devices,The first product is the K-Clip, a transcatheter tricuspid annuloplasty system with internationally leading technology.。K-Clip has entered the "Green Channel" for special review of innovative medical devices in China.`, and completed the registration clinical study, submitted the registration application to the National Medical Products Administration (NMPA), and is expected to be approved this year.`

HuiHe Healthcare ownsMore than 120 R&D personnel, with an 8,000-square-meter R&D and production facility,Always with 230+ patents, including 170 invention patents and more than 10 PCTs.The company has established good cooperation with multiple scientific research institutes, such as Zhongshan Hospital Affiliated to Fudan University and the Institute of Health and Environmental Technology of Soochow University. Since its establishment,HuiHe Healthcare has successively completed angel round, A round, A+ round, and B round financing., with investments from well-known institutions such as IDG Capital, Oriza Ventures, Boyuan Capital, Guofang Capital, SDIC Venture, Legend Star, and Shanghai Sci-Tech Innovation.